Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
A Phase I, open-label, non-randomized, sequential dose escalation cohort trial of the safety,
tolerability, and maximum tolerated dose (MTD) of AP23573 when administered intravenously as
a 30-minute infusion, once daily for five days, repeated every two weeks, to patients with
progressive or recurrent malignant glioma.